COMP <GO>
ICLR vs ABBV // PIOTROSKI F-SCORE QUALITY
ICON plc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ICLR 5
— ABBV 9
■ METRIC PARITY
LAST: $211.36 (-1.91%) • MKT CAP: $16.50B
piotroski-score
7/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICLR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICLR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 29.00% | -25.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.7x | 33.3x | -1.60 | ICLR | /valuation <GO> |
| Free Cash Flow Yield | 5.22% | 3.47% | +1.75 | ICLR | /fcf-yield <GO> |
| Operating Margin | 5.40% | 24.60% | -19.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 2.80% | 6.90% | -4.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 0.80% | 8.60% | -7.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.20 | 5.33 | -3.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | ICLR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.1 | 72.8 | +1.29 | ICLR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 66.9x | 113.1x | -46.20 | ICLR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.50B | $513.86B | -$497.36B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICLR REV | ABBV REV | ICLR GROSS % | ABBV GROSS % | ICLR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.25B | $61.16B | 44.0% | 70.2% | $862.0M | $17.82B |
| FY 2024 | $8.19B | $56.33B | 28.6% | 70.0% | $1.12B | $17.83B |
| FY 2023 | $8.05B | $54.32B | 44.0% | 44.0% | $798.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICLR // BETA 1.08
ABBV // BETA 1.15